Crucell and Scripps find antibody for universal flu vax

Researchers at Crucell and the Scripps Research Institute have discovered a new antibody that could lead to a universal flu vaccine. According to animal test results, the antibody, CR6261, neutralized multiple flu strains, including H3N2, which killed 1 million people in Asia during the late 1960s. And researchers have found CR8020 is a complementary antibody, which fights the flu strains not affected by CR6261. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.